Join this webinar to discover how reporter luciferase-based assay pyrogen detection can provide an accurate and rapid alternative to rabbit pyrogen test (RPT) for challenging pharmaceuticals.
Pyrogen testing of parenteral pharmaceuticals and medical devices is essential for patients’ safety. Recently, the monocyte activation test (MAT), which utilises the immune response of human monocytes instead of rabbits to detect pyrogens, has gained attention; however, conventional ELISA-based MAT systems suffer from insufficient reproducibility and long assay times.
The rabbit pyrogen test (RPT) was removed from the European Pharmacopoeia, increasing demand for MAT and testing methods that enable accurate and highly efficient measurements.
Next-generation pyrogen detection kit LumiMAT addresses these issues with a more accurate and simplified testing method. This approach enables accurate and rapid detection (five hours) of various pyrogens and simplifies workflow compared to ELISA-based MAT.
Additionally, improved sample throughput and reduced measurement variability enhance assay stability and time efficiency, enabling more practical test designs.
This webinar presents primary validation and method suitability test results conducted in accordance with Ph. Eur. 2.6.30, demonstrating its efficacy across multiple pharmaceuticals.
Join this webinar to learn find out how the addition of supplements can improve the NEP spike recovery in previously hard-to-test pharmaceuticals.
Validation data will be presented that illustrates use in actual pharmaceutical products, as well as the practical benefits of adding supplements to enhance assay performance and confirming the method’s applicability across diverse pharmaceutical formulations.
Key learning points
- Find out about the development of a new MAT method using a luciferase assay as an accurate and rapid alternative to RPT
- Benefits of reporter assay based-MAT, including how it can significantly reduce testing time and simplify operation, leading to decreased variability in results between testers, and how using a cell line instead of PBMCs ensures lot-to-lot variation and stable supply.
- How to perform primary validation and method suitability tests in accordance with Ph. Eur. 2.6.30.
- Case Studies: improving NEP spike recovery with supplement addition and high throughput testing using 384-well plates
Vivien Knospe - Associate Sales Manager – Pyrogen & Endotoxin Specialist, FUJIFILM WAKO - Vivien is an Associate Sales Manager – Endotoxin and Pyrogen Specialist at FUJIFILM WAKO Chemicals Europe GmbH since August 2023. She is TÜV-certified Quality representative (ISO 9001) and GMP Manager and earned both Bachelor and Master degrees in Biochemistry.
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
The webinar will be taking place on 2nd September 2026 3PM (BST)
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.